Summary
This document is an infosheet detailing the transformation in pharmaceutical data management, particularly in the context of the COVID-19 pandemic. It outlines the challenges faced by biopharmaceutical companies in drug development, emphasizing the need for improved data management systems to enhance efficiency and reduce costs. The document discusses the current reliance on siloed data systems and the implications of poor data management on drug development timelines and costs. It presents BioPharmaceutical Lifecycle Management (BPLM) as a solution to integrate data across the entire development lifecycle, highlighting its potential to streamline processes and improve operational efficiency. The infosheet also describes the capabilities of the IDBS Polar platform, which supports data collection, analysis, and regulatory compliance, aiming to accelerate the time to market for new therapies. Overall, it emphasizes the importance of digital transformation in overcoming existing barriers and enhancing the biopharmaceutical industry's ability to deliver effective treatments.
